Legend Biotech (LEGN) Long-Term Deferred Tax (2019 - 2021)

Legend Biotech has reported Long-Term Deferred Tax for 3 years, with the latest figure at $22.8 million in Q4 2021.

• For the quarter ending Q4 2021, Long-Term Deferred Tax fell 25.98% year-over-year to $22.8 million; the trailing twelve-month figure through Dec 2021 stood at $22.8 million (down 25.98% YoY), and the FY2021 full-year result was $22.8 million, down 25.98% from the prior year.
• Long-Term Deferred Tax for Q4 2021 stood at $22.8 million, down from $30.8 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $30.8 million in Q4 2020, with the low at $5.7 million in Q4 2019.
• Historically, Long-Term Deferred Tax has averaged $19.8 million across 3 years, with a median of $22.8 million in 2021.
• Annual changes were most pronounced in 2020 — Long-Term Deferred Tax jumped 438.86% — and 2021, when it fell 25.98%.
• Legend Biotech's Long-Term Deferred Tax stood at $5.7 million in 2019, then jumped by 438.86% to $30.8 million in 2020, then slipped by 25.98% to $22.8 million in 2021.
• The last three Long-Term Deferred Tax figures came in at $22.8 million (Q4 2021), $30.8 million (Q4 2020), and $5.7 million (Q4 2019), per Business Quant data.